Novadiscovery   Report issue

For profit Phase 1 Phase 3
Founded: Lyon France (2010)

Organization Overview

First Clinical Trial
2016
NCT02849613
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

NOVADISCOVERY SAS, France

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous adipose-derived mesenchymal stem cells (1 trial)

Drugs in Phase 1 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stroke (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2